Cellumed is showing strong performance. It appears to be influenced by news that domestic companies related to spinal surgery have consecutively obtained approval from the U.S. Food and Drug Administration (FDA).
As of 2:05 PM on the 30th, Cellumed is trading at 3,980 KRW, up 3.65% from the previous day.
Previously, Cellumed developed surgical robot software last year in collaboration with Curexo.
Additionally, with government support, they are developing a process that improves the production yield of bone morphogenetic protein (BMP2) by more than five times compared to before. BMP2 is a growth factor that accelerates bone regeneration when applied to damaged areas such as the spine and teeth. The global market size is estimated to reach approximately 1 trillion KRW.
Recently, Curexo's spinal surgery robot, Qsys Spine, a renewed product, also received FDA approval. Qsys Spine is a spinal surgery robot that guides and fixes spinal pedicle screws to precise locations. It is expected that the market share of domestic products in the overseas spinal medical device market will increase.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
